Search results for "Chloride"

showing 10 items of 1691 documents

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene

2009

Abstract Background Polymorphisms of cytochrome P450 2D6 (CYP2D6) have a significant effect on the pharmacokinetics of most tricyclic antidepressants. More than 150 alleles lead to four distinct phenotypes of drug metabolism. The phenotypes are described as ultrarapid, extensive, intermediate, and poor metabolizers. Therapeutic plasma levels of CYP2D6 substrates may be difficult to achieve. Here we describe a rapid and reliable procedure for CYP2D6*4, *3, *6, and *9 genotyping. Design and methods Serum concentrations of venlafaxine and its pharmacologically active metabolite, O-desmethylvenlafaxine, were measured in patients treated with the antidepressant venlafaxine, a substrate of CYP2D6…

AdultMaleCYP2D6GenotypeDNA Mutational AnalysisMolecular Sequence DataClinical BiochemistrySingle-nucleotide polymorphismBiologyPolymerase Chain ReactionSensitivity and Specificitydigestive systemGene DuplicationGene duplicationGenotypeHumansAlleleskin and connective tissue diseasesGeneGenotypingAllelesSequence DeletionGeneticsPolymorphism GeneticBase SequenceDepressionVenlafaxine HydrochlorideReproducibility of ResultsSequence Analysis DNAGeneral MedicineMiddle AgedCyclohexanolsMolecular biologyReal-time polymerase chain reactionCytochrome P-450 CYP2D6MutationAntidepressive Agents Second-GenerationFemaleClinical Biochemistry
researchProduct

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

1996

A double-blind, randomized, parallel study in 167 hospitalized patients with major depression and melancholia was conducted to determine if rapidly escalated doses of venlafaxine produced an earlier response, compared with rapidly escalated doses of imipramine. The daily dose of venlafaxine was rapidly increased to 375 mg/day over a five-day period, was maintained at this level for 10 days, and then was reduced to 150 mg/day for the remainder of the study. The imipramine dose was rapidly increased to 200 mg/day over five days and was maintained at this level to the end of the study. The primary efficacy variables were time to response and time to sustained response on the HAM-D and MADRS. N…

AdultMaleImipraminePersonality Inventorymedicine.medical_treatmentVenlafaxineAntidepressive Agents TricyclicImipramineDrug Administration ScheduleDouble blindDouble-Blind MethodMelancholiamedicineHumansBiological PsychiatryDepression (differential diagnoses)Rapid responseChemotherapyDepressive DisorderDose-Response Relationship DrugVenlafaxine HydrochlorideParallel studyMiddle AgedCyclohexanolsPsychiatry and Mental healthTreatment OutcomeAnesthesiaAntidepressive Agents Second-GenerationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Moni…

1996

Venlafaxine is a new nontricyclic antidepressant inhibiting the reuptake of serotonin, noradrenaline, and, to a lesser extent, dopamine without antagonizing cholinergic, histaminergic, or noradrenergic receptors. Significantly, in a first placebo-controlled safety and efficacy study, high doses of venlafaxine increased blood pressure in some study subjects. In order to investigate further the effect of subchronic antidepressant drug treatment on blood pressure and heart rate, the effects of a conventional tricyclic (imipramine) and a structurally different phenethylamine antidepressant (venlafaxine) were compared. Sixteen inpatients with major depression (melancholic type) were treated for …

AdultMaleImipramineVenlafaxine HydrochlorideHemodynamicsBlood PressureVenlafaxineAntidepressive Agents TricyclicImipramineDouble-Blind MethodHeart RateHeart ratemedicineHumansPharmacology (medical)Psychiatric Status Rating ScalesDepressive Disorderbusiness.industryVenlafaxine HydrochlorideGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle AgedCyclohexanolsPsychiatry and Mental healthBlood pressureAnesthesiaCirculatory systemAntidepressive Agents Second-GenerationAntidepressantFemalebusinessmedicine.drugPharmacopsychiatry
researchProduct

Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

2016

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…

AdultMaleLung NeoplasmsTime FactorsAntineoplastic AgentsKaplan-Meier EstimateAdult; Aged; Antineoplastic Agents; Carcinoma Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Time Factors; Treatment OutcomeResponse evaluation criteria in solid tumorDisease-Free SurvivalErlotinib Hydrochloridenon–small cell lung cancerPositron Emission Tomography Computed TomographyHumansProspective StudiesNon-Small-Cell LungAgedCarcinomaMiddle AgedCarcinoma non-small-cell lungEORTCTreatment OutcomeRECISTResponse evaluation criteria in solid tumorsFemalePositron-emission tomographyPERCISTDiagnosi18F-FDG PET
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

2015

Objective: We aimed to clarify whether fingolimod has direct effects on antigen-presenting cells in multiple sclerosis patients. Methods: Frequency and phenotype of directly ex vivo dendritic cells and monocytes were analyzed in 43 individuals, including fingolimod-treated and untreated multiple sclerosis patients as well as healthy subjects. These cells were further stimulated with lipopolysaccharide to determine functional effects of fingolimod treatment. Results: Absolute numbers of CD1c+ dendritic cells and monocytes were not significantly reduced in fingolimod-treated patients indicating that fingolimod did not block the migration of antigen-presenting cells to peripheral blood. CD86 w…

AdultMaleMultiple Sclerosismedicine.medical_treatmentMonocytesYoung AdultMedicineHumansAntigen-presenting cellCD86business.industryFingolimod HydrochlorideMonocyteDendritic cellImmunotherapyDendritic CellsMiddle AgedFingolimodCytokinemedicine.anatomical_structureNeurologyImmunologyCytokinesFemaleNeurology (clinical)businessEx vivoImmunosuppressive Agentsmedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell …

2007

On the basis of a preceding phase I study, the current trial explored bendamustine in combination with mitoxantrone and rituximab (BMR) in patients with stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL) with or without prior rituximab containing chemo-immunotherapy (R-chemo) treatment. Therapy consisted of bendamustine 90 mg/m(2) days 1 + 2, mitoxantrone 10 mg/m(2) day 1, rituximab 375 mg/m(2) day 8. Treatment was repeated on day 29 for a total of four cycles. Between 3 April and 04 July, 57 patients were recruited from 24 participating institutions, 39% of whom had received prior R-chemo therapy. Median age was 66 years (40 - 83). Lymphoma subtypes were …

AdultMaleOncologyBendamustineCancer Researchmedicine.medical_specialtyPathologyPhases of clinical researchLymphoma Mantle-CellAntibodies Monoclonal Murine-DerivedInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansLymphoma FollicularSurvival analysisAgedAged 80 and overSalvage TherapyMitoxantronebusiness.industryLymphoma Non-HodgkinRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLymphomaClinical trialTreatment OutcomeOncologyNitrogen Mustard CompoundsMonoclonalFemaleRituximabMitoxantroneRituximabbusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Effect of phenylephrine on static and dynamic accommodation

2018

Purpose We tested the hypothesis that changes in accommodation after instillation of Phenylephrine Hydrochloride (PHCl) observed in some studies could be caused by changes in optics. Methods We performed two experiments to test the effects of PHCl on static and on dynamic accommodation in 8 and 6 subjects, respectively. Objective wavefront measurements were recorded of the static accommodation response to a stimulus at different distances or dynamic accommodation response to a sinusoidally moving stimulus (between 1 and 3 D of accommodative demand at 0.2 Hz). The responses were characterized using two methods: one that takes into account the mydriatic optical effects on the accommodation pr…

AdultMaleOriginal articleAccommodationMydriaticsmedicine.medical_specialtygenetic structuresPhenylephrine03 medical and health sciences0302 clinical medicineCiliary bodyOphthalmologymedicineHumansAcomodaciónPhenylephrineMathematicsbusiness.industryCiliary BodyMétricaPupil sizeAccommodation OcularPhenylephrine Hydrochlorideeye diseasesCiliary musclemedicine.anatomical_structure030221 ophthalmology & optometryMetricsFemalesense organsbusinessFenilefrinaAccommodation030217 neurology & neurosurgeryOptometrymedicine.drugJournal of Optometry
researchProduct